XBIT - XBiotech Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
8.22
-0.38 (-4.42%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close8.60
Open8.65
Bid8.16 x 1800
Ask8.90 x 1000
Day's Range8.07 - 8.71
52 Week Range2.13 - 11.74
Volume132,533
Avg. Volume196,482
Market Cap337.115M
Beta (3Y Monthly)0.41
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
All
News
Press Releases
  • GlobeNewswire

    Dr. Seth Forman to Chair XBiotech’s Second Phase 2 Study of Bermekimab in Atopic Dermatitis

    XBiotech (XBIT) announces that Seth Forman, M.D., will Chair the Company’s upcoming randomized, double-blind, placebo controlled Phase 2 study in Atopic Dermatitis (AD). This second Phase 2 study of bermekimab to treat moderate to severe AD in adults will build on results of a recently completed randomized study that showed rapid improvement in inflammatory lesions and pruritus.

  • GlobeNewswire

    XBiotech Adds Dr. Peter Libby, Renowned Cardiologist and Research Pioneer in Inflammation and Cardiovascular Disease, to its Corporate Board

    XBiotech Inc. (XBIT) announced today that Peter Libby, M.D., has been appointed to the Company’s Corporate Board of Directors.  Dr. Libby has played a pioneering role in discovering how inflammation leads to cardiovascular disease. Dr. Libby is a practicing cardiovascular specialist at Brigham and Women’s Hospital in Massachusetts and he is Mallinckrodt Professor of Medicine at Harvard Medical School.

  • GlobeNewswire

    Medical Research Council Funds Phase 2 Multi-Center Study of XBiotech’s Bermekimab in Advanced Cancer Patients

    XBiotech (XBIT) announced today that the Medical Research Council (MRC), part of UK Research and Innovation, has awarded funding to study bermekimab therapy in a Phase 2 multi-center study in advanced cancers.

  • GlobeNewswire

    XBiotech Wins “Commercial Real Estate Award for Industrial Development” for its Headquarters in Austin, Texas

    XBiotech Inc. (XBIT) announced today that it is the recipient of the first place 2019 Commercial Real Estate Award for Industrial Development, chosen by the Austin Business Journal. XBiotech USA Inc. received the award for its integrated R&D, administrative, and manufacturing facility located just 15 minutes from downtown Austin. XBiotech began construction of its state-of-the-art facility in 2015 as part of a master plan to build its worldwide operations headquarters.

  • GlobeNewswire

    XBiotech Announces Dr. Alice Gottlieb to Chair Upcoming Phase 2 Study of Bermekimab in Hidradenitis Suppurativa

    XBiotech (XBIT) announces that Alice Gottlieb M.D., Ph.D., will Chair the Company’s upcoming Phase II study in Hidradenitis Suppurativa (HS). Dr. Gottlieb is Medical Director of dermatology at the Mount Sinai Beth Israel Campus, and Clinical Professor at the Icahn School of Medicine at Mount Sinai.

  • GlobeNewswire

    XBiotech Added to Russell 3000® Index

    XBiotech Inc. (XBIT) announced today that the Company has been added to the preliminary list of the broad market Russell 3000® Index, which will take effect after US market close on June 28, as part of the 2019 Russell indexes reconstitution. Membership in the Russell 3000® Index, which remains in place for one year, means automatic inclusion in the large-cap Russell 1000® Index or small-cap Russell 2000® Index as well as the appropriate growth and value style indexes. Annual reconstitution of the Russell indexes captures the 4,000 largest US stocks as of May 10th, ranking them by total market capitalization.

  • GlobeNewswire

    XBiotech Announces Closing of Public Offering of Common Shares

    XBiotech Inc. (XBIT) today announced the closing of its previously announced underwritten public offering of 4,848,485 of its common shares at a public offering price of $8.25 per share.  In addition, XBiotech has granted the underwriter a 30-day option to purchase up to an additional 351,515 common shares at the public offering price, less underwriting discounts and commissions. Piper Jaffray acted as the sole underwriter in the offering.

  • GlobeNewswire

    XBiotech Announces Pricing of Public Offering of Common Shares

    XBiotech Inc. (XBIT) today announced the pricing of an underwritten public offering of 4,848,485 of its common shares at a public offering price of $8.25 per share.  The offering is expected to close on or about June 4, 2019, subject to the satisfaction of customary closing conditions. In addition, XBiotech has granted the underwriter a 30-day option to purchase up to an additional 351,515 common shares at the public offering price, less underwriting discounts and commissions. Piper Jaffray is acting as the sole underwriter in the offering.

  • GlobeNewswire

    XBiotech Announces Public Offering of Common Shares

    XBiotech Inc. (XBIT) today announced that it has commenced an underwritten public offering of common shares, subject to market and other conditions.   XBiotech intends to grant the underwriter in the offering a 30-day option to purchase additional common shares. Piper Jaffray is acting as the sole underwriter in the offering. The common shares are being offered pursuant to an effective shelf registration statement on Form S-3 previously filed with and declared effective by the Securities and Exchange Commission.  The prospectus supplement and accompanying prospectus relating to the offering contain important information relating to the XBiotech common shares.

  • GlobeNewswire

    XBiotech Announces Plan to Launch Randomized Phase 2b Study of Bermekimab in Hidradenitis Suppurativa

    XBiotech (XBIT) announced plans to advance its dermatology program for its true human antibody bermekimab with the launch of a randomized, double-blind, placebo controlled, Phase 2b clinical study in patients with moderate to severe Hidradenitis Suppurativa (HS). This Phase 2b study will evaluate safety and efficacy of bermekimab at different subcutaneous doses compared with placebo. The Company expects the first patient to be enrolled during the third quarter of 2019.

  • GlobeNewswire

    XBiotech Announces Enrollment Completion, Positive Findings for Bermekimab in Pancreatic Cancer Study

    The study is being conducted and led by principal investigator Andrew Hendifar, M.D., Medical Oncology lead for the Gastrointestinal Disease Research Group and Co-Director of Pancreas Oncology at Cedars-Sinai Medical Center2.  A total of 18 patients are enrolled in the study.

  • GlobeNewswire

    Breakthrough Results from Phase 2 Clinical Trial of Bermekimab in the Treatment of Atopic Dermatitis (AD) to be Presented on March 2, 2019 at American Academy of Dermatology Annual Meeting

    XBiotech (XBIT) announced today that breakthrough results from its Phase 2 clinical trial of its antibody therapy, bermekimab, are being presented tomorrow at a late-breaking oral presentation during the annual meeting of the American Academy of Dermatology (AAD) being held  in Washington, DC. The presentation titled, “Bermekimab is a Rapid and Effective Treatment for Atopic Dermatitis (AD)” will take place on Saturday, March 2 at 1:10pmET in Ballroom A and will be presented by international dermatology expert, and lead researcher in the development of approved therapies for atopic dermatitis, Eric Simpson, M.D, M.C.R. Professor of Dermatology at Oregon Health & Science University, School of Medicine.

  • ACCESSWIRE

    These 4 Biotech Stocks Are Leading The Industry

    Premier Health Group (PHGRF) (PHGI), Neon Therapeutics Inc (NTGN), Bionano Genomics Inc (BNGO), and XBiotech Inc (XBIT) represent four biotech companies working to champion new treatments for consumers in the space. The Company has magnetized investors looking for opportunities in the biotech sector by strategically investing in products and services that demonstrate Premier's dedication to the industry, as well to patients simply looking for a means of feeling better. Premier Health Group (PHGRF) (PHGI) announced towards the end of last month that, further to itsnew release dated January 10, 2019, the Company has acquired all outstanding securities of Cloud Practice Inc. As a result of the acquisition, Cloud Practice's Founders, including CEO Jordan Visco, and entire support team, consisting of several software developers and sales staff, will join and work alongside the Premier Health team to offer tools and resources providing for better efficiency on a day-to-day basis for both physicians and customers.

  • GlobeNewswire

    Dr. Eric Simpson to Present Bermekimab Results in Atopic Dermatitis at 2019 AAD Annual Meeting

    XBiotech (XBIT) announced today that findings from its open label, multicenter study using bermekimab to treat patients with moderate to severe atopic dermatitis (AD) will be presented at the “Late-Breaking Research: Clinical Trials” forum at the American Academy of Dermatology (AAD) Annual Meeting being held March 1-5, 2019 in Washington, D.C. The oral presentation titled, “Bermekimab is a Rapid and Effective Treatment for Atopic Dermatitis (AD)”, will be delivered by international expert and advisor for XBiotech, Eric Simpson, M.D., M.C.R., Professor of Dermatology at Oregon Health & Science University School of Medicine, during the afternoon session on March 2nd, 2019.

  • GlobeNewswire

    Dr. Alice Gottlieb to Present Hidradenitis Suppurativa Findings at American Academy of Dermatology Annual Meeting

    AUSTIN, Texas, Jan. 28, 2019 -- XBiotech (NASDAQ: XBIT) announced today that Dr. Alice Gottlieb, M.D., Ph.D., will be giving the presentation “Bermekimab Shows Efficacy for.

  • GlobeNewswire

    Bermekimab Successfully Treats Hidradenitis Suppurativa, Including Significant Reduction in Pain

    XBiotech (XBIT) announced today the successful outcome of its multicenter, open label, confirmatory study using bermekimab to treat patients with moderate to severe Hidradenitis Suppurativa (HS).  Primary and key secondary endpoints were met in this study with significant, differentiating findings.  The Company previously published data from its double-blind placebo controlled study in HS using bi-weekly, intravenous infusions of bermekimab in which safety and primary efficacy endpoints were met.

  • GlobeNewswire

    XBiotech Announces Publication of Post-Hoc Analysis for Phase III Colorectal Cancer Study

    The manuscript, entitled, “Interleukin-1 Receptor Antagonist (IL-1ra) Levels Predict Favorable Outcome after Bermekimab, a First-in-Class True Human Interleukin-1α Antibody,  in a Phase III Randomized Study of Advanced Colorectal Cancer”, has been published online in the journal OncoImmunology. The findings report that patients with relatively low levels of IL-1ra or IL-6 were more likely to respond to bermekimab therapy and achieve the study’s primary endpoint. The study’s primary endpoint measured a combination of physical symptoms—pain, fatigue, anorexia and muscle wasting—which tend to worsen with advanced cancer, to assess whether these symptoms stabilized or improved with treatment.

  • GlobeNewswire

    XBiotech’s Results from Phase 2 Atopic Dermatitis Study Suggest New Drug to Treat Skin Disease

    XBiotech (XBIT) announced today that its open label, proof of concept, multicenter study using bermekimab to treat patients with moderate to severe atopic dermatitis (AD) has completed and the study met all primary and secondary endpoints.

  • GlobeNewswire

    XBiotech Announces Successful Completion of GMP Audit

    XBiotech Inc. (XBIT) today announced a successful GMP (Good Manufacturing Practices) audit by Eurofins Amatsigroup. The audit was conducted in connection with XBiotech’s distribution in Europe of its US-manufactured biological drug product. XBiotech manufactures bermekimab at its campus facility in Austin, Texas and regularly ships the drug to clinics in various countries in the European Union and the United Kingdom.

  • GlobeNewswire

    Detailed Research: Economic Perspectives on Jason Industries, XBiotech, Dynatronics, Evolving, CTI BioPharma, and Charles & Colvard — What Drives Growth in Today's Competitive Landscape

    NEW YORK, Nov. 23, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.

  • GlobeNewswire

    XBiotech Highlights Third Quarter Developments for 2018

    XBiotech Inc. (XBIT) today provided an update on recent company developments in its third quarter Form 10-Q filing with the SEC. The Company reports that it continues to make important progress in its clinical and pre-clinical programs in addition to other corporate initiatives. In April 2018, XBiotech announced the launch of a Phase 2, open label clinical trial to evaluate the Company’s True Human™ monoclonal antibody, bermekimab, in patients with moderate to severe Atopic Dermatitis (AD).